Q2 2025 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) achieved a major milestone by delivering over $100 million in revenue in a single quarter for the first time.
- The company reported a 49% year-over-year increase in second-quarter revenues, with exome and genome revenues up 69% from the same quarter last year.
- GeneDx Holdings Corp (WGS) has established itself as the number one genetic testing brand among pediatric healthcare providers, holding an 80% market share among geneticists.
- The company is expanding its market reach, with significant growth opportunities in the NICU and general pediatrics markets, driven by new guidelines from the American Academy of Pediatrics.
- GeneDx Holdings Corp (WGS) reported a record high adjusted gross margin of 71%, driven by favorable mix shifts, improving reimbursement, and lower costs.
- Despite the strong performance, the company faces challenges in expanding its reach to general pediatricians, which is expected to take 18 to 24 months for broader adoption.
- The company anticipates a higher denial rate as it enters new indications and call points, which could impact reimbursement rates.
- GeneDx Holdings Corp (WGS) is still working on simplifying the ordering process and report interpretation for non-specialists, which is crucial for expanding into the general pediatrician market.
- The company is facing competition in the genomic testing market, which could impact its market share and growth potential.
- There is a reliance on Medicaid coverage expansion, which is uncertain and could affect the company's revenue growth if new states do not pick up coverage.
Good day and thank you for standing by. Welcome to the GeneDX second-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference over to Sabrina Dunbar, Investor Relations, please go ahead.
Thank you, operator, and thank you to everyone for joining us today. On the call we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GDX released financial results for the second quarter ended June 30, 2025.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, updated 2025 guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and are -- and only reflect our view as of today July 29, and we are under no obligation to update.
When testing our results, we refer to non-GAAP measures
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
